Treatment for Non-Alcoholic Steatohepatitis (NASH)

Introduction to NASH Treatment

The American Association for the Study of Liver Diseases recommends lifestyle modifications, including weight loss of 7-10%, Mediterranean diet, and regular exercise, as the cornerstone of NASH treatment, with pharmacotherapy reserved for biopsy-proven NASH with fibrosis 1, 2, 3

Weight loss of 7-10% is the primary goal for overweight/obese patients with NASH, as it significantly improves liver histology, reduces steatosis, inflammation, and can reverse NASH 1, 2
Even modest weight loss (5-7%) can improve hepatic steatosis and components of the NAFLD activity score 2
The American Heart Association recommends a Mediterranean diet, characterized by reduced carbohydrate intake, increased monounsaturated and omega-3 fatty acid intake, and rich in fruits, vegetables, whole grains, legumes, nuts, and olive oil, as the most strongly recommended dietary pattern for NASH 4
Limiting excess fructose consumption, avoiding processed foods with added sugars, replacing saturated fats with polyunsaturated and monounsaturated fats, and avoiding processed foods, fast food, and commercial bakery goods are specific dietary modifications recommended for NASH patients 4
The American College of Sports Medicine recommends both aerobic and resistance training as effective ways to reduce liver fat in NASH patients 1
Vigorous exercise provides greater benefit than moderate exercise for NASH and fibrosis, and any increase in physical activity over previous levels is beneficial compared to continued inactivity 1

The European Association for the Study of the Liver recommends pharmacological treatments, including vitamin E and pioglitazone, for patients with biopsy-proven NASH and fibrosis 2
Vitamin E (800 IU/day) is recommended for non-diabetic adults with biopsy-confirmed NASH, improving liver histology through antioxidant properties, but with potential concerns about increased risk of all-cause mortality, hemorrhagic stroke, and prostate cancer with long-term use 2, 3, 5
Pioglitazone (30 mg daily) is effective for patients with biopsy-proven NASH with or without diabetes, improving all histological features except fibrosis, but with side effects including weight gain, bone fractures in women, and rarely congestive heart failure 1, 2, 5, 6

For NASH patients with type 2 diabetes, the American Diabetes Association recommends considering pioglitazone, which has the strongest evidence for NASH treatment in diabetic patients, and GLP-1 receptor agonists, which show promise for NASH treatment, though evidence is still emerging 6

For NAFL (simple steatosis) or NASH with minimal fibrosis (F0-F1), the American Gastroenterological Association recommends focusing on lifestyle modifications only, with no specific liver-directed pharmacotherapy recommended 2, 7
For NASH with significant fibrosis (F2-F3), the American Association for the Study of Liver Diseases recommends intensive lifestyle modifications and considering pharmacotherapy, including vitamin E for non-diabetic patients and pioglitazone for diabetic patients 1, 2, 7
For NASH with cirrhosis (F4), the European Association for the Study of the Liver recommends lifestyle modifications with careful monitoring, limited evidence for pharmacotherapy, and hepatocellular carcinoma surveillance with ultrasound ± AFP every 6 months 5, 7

Weight loss of more than 7% is associated with decreased necroinflammation, while 3-5% improves steatosis alone, as reported by the Mayo Clinic Proceedings 8
Structured weight loss programs are superior to general education alone, with two-thirds of patients in an intensive intervention group no longer meeting NASH criteria after 48 weeks, according to the Mayo Clinic Proceedings 8
All currently recommended pharmacologic treatments for NASH require a histologic diagnosis prior to initiation, as stated in the Mayo Clinic Proceedings 8
Bariatric surgery may be considered for morbidly obese patients who meet other medical criteria, with nearly 85% of obese patients with biopsy-proven NASH having histologic resolution at one year following bariatric surgery, as reported by the Mayo Clinic Proceedings 8
A prospective study showed that bariatric surgery may lead to histologic resolution in obese patients with biopsy-proven NASH, but data to support bariatric surgery as a specific treatment for NASH is still lacking, as noted in the Mayo Clinic Proceedings 8

The Mayo Clinic recommends discontinuing hepatotoxic medications, including corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid, in patients with NASH 9

The American College of Cardiology and other guideline societies recommend using statins for dyslipidemia in NASH patients, as they are safe and have beneficial pleiotropic properties, although the specific citation for this is not provided, the general principle is supported by various guidelines, including those from the American Heart Association 9